BiaCarta

Allele Biotech Acquires BioCarta’s Distribution Business

Allele Biotechnology & Pharmaceuticals, Inc. is pleased to announce that as of January 1st, 2014, it has acquired the distribution business of BioCarta. This transaction will strengthen Allele Biotech’s presence in the antibody field, enhancing a broad customer and partnership base to further its plan in clinical diagnostics. Biocarta has been a leader in the field of gene expression for 10 years and has contributed immensely through its world leading effort of charting molecular biology pathways. The gene function maps published by Biocarta have been used and referred to by the NIH through the National Center for Biological Information and National Library of Medicine.

Among its well-regarded distribution business, for the past 11 years BioCarta had been the US and Canada’s exclusive distributor of Immune Function Assay Kits for Flow Cytometric Analysis by Glycotope Biotechnology, GmbH. These kits are clinically approved blood cell diagnostic assay products that are also heavily used for non-clinical blood studies.

Allele Biotech has recently launched a major business plan to create a large number of nano antibodies (nAbsTM). The nAbTM line will be great research tools for immunoprecipitation (co-IP), immunohistochemistry (IHC), Western blotting, co-crystallization, biologics purification. Additionally, nAbsTM willbe suitable for diagnostic assays because the single domain antibodies derived from camelid family animals are sturdy, specific, and low-cost. The inclusion of the BioCarta distribution channels in the antibody and pathway reagent fields will help speed up Allele Biotech’s expansion.

Tags: , , , , , ,

Thursday, January 16th, 2014 Allele Mail Bag No Comments